



Mark D. Alexander

Partner

New York

TEL NY 212.728.2237

TEL CT 860.275.8130

malexander@axinn.com

PRACTICE AREAS

Antitrust

Litigation

EDUCATION

JD, cum laude – Cornell Law School
(1992)

BA – Indiana University (1989)

ADMISSIONS

Connecticut

New York

Tennessee

U.S. Court of Appeals for the Fourth
Circuit

U.S. Court of Appeals for the Seventh
Circuit

U.S. District Court District of
Connecticut

U.S. District Court Southern District of
New York

PROFILE

Mark Alexander has more than 30 years of experience representing pharmaceutical and life sciences companies, and other clients across a wide range of industries, in complex deal reviews by global regulators and high-stakes antitrust litigation.

Mark provides sophisticated and practical counsel to help clients navigate the antitrust regulatory process in US, Europe, and China and gain clearance for billion-dollar deals. His experience includes advising Thermo Fisher Scientific in numerous multibillion-dollar deals, including its recent \$1.85 billion acquisition of PeproTech Inc.

As lead antitrust litigation counsel, Mark has particularly deep experience in defending clients against claims under Section 7 of the Clayton Act and Section 2 of the Sherman Act. He also has broad commercial litigation and arbitration experience representing clients across a spectrum of industries, including the communications, oil and gas, consumer products, chemicals, and healthcare sectors.

Prior to joining Axinn, Mark practiced in the New York and London offices of Sullivan & Cromwell LLP.

PROFESSIONAL ACTIVITIES

- American Bar Association, Section of Antitrust Law
- Connecticut Bar Association


EXPERIENCE

Transactions

- Represented Thermo Fisher Scientific in its \$912 million acquisition of CorEvitas.
- Represented Thermo Fisher Scientific in its \$2.6 billion acquisition of The Binding Site.
- Represented Thermo Fisher Scientific in its \$1.85 billion acquisition of PeproTech Inc.
- Lead antitrust counsel to Centerbridge Partners portfolio company, KIK Custom Products Inc., in its acquisition of NC Brands LP.
- Represented Thermo Fisher Scientific in its \$13.6 billion acquisition of Life Technologies.
- Represented Thermo Fisher Scientific in its \$12.5 billion tender offer for QIAGEN N.V.
- Represented Johnson Controls in the \$2 billion sale of its Scott Safety business to 3M.
- Represented Thermo Fisher Scientific in its \$7.2 billion acquisition of Patheon N.V.
- Represented McKesson in its \$1.4 billion acquisition of CoverMyMeds LLC.
- Represented Ball Corporation in its \$6.85 billion acquisition of Rexam PLC.
- Represented Thermo Fisher Scientific in its \$4.2 billion acquisition of FEI Company.
- Represented Charles River Laboratories International Inc. in its \$585 million acquisition of WIL Research.
- Represented Thermo Fisher Scientific in its \$1.3 billion acquisition of Affymetrix.
- Represented SunGard Higher Education in its \$1.77 billion sale of SunGard Higher Education to Datatel.
- Represented Cingular in its \$41 billion acquisition of AT&T Wireless.

Litigation

- Represented Watson Laboratories (now Actavis) in obtaining a victory in the US Court of Appeals for the Fourth Circuit that helped



expedite the entry of its generic version of Celebrex® to market.

- Represented national insurance broker Brown & Brown in obtaining summary judgement by the Connecticut Supreme Court dismissing all claims brought by Blumberg Associates Worldwide. Briefed and argued the appeal, resulting in an unanimous affirmance of a district court decision.
- Represented Watson Laboratories Inc. in securing summary judgment in litigation against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia.

HONORS

- *Best Lawyers* in America (2018 – 2023)
- *Cornell Law Review*, Symposium Editor
- American Jurisprudence Awards, Civil Procedure, Criminal Law, and Torts

